<DOC>
	<DOCNO>NCT00374296</DOCNO>
	<brief_summary>In study , MGCD0103 , new anticancer drug investigation , give three time per week elderly patient previously untreated acute myelogenous leukemia/high risk myelodysplastic syndrome adult relapsed/refractory disease .</brief_summary>
	<brief_title>MGCD0103 Elderly Patients With Previously Untreated AML/High Risk MDS Adults With Relapsed/Refractory Disease</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Mocetinostat</mesh_term>
	<criteria>Pathologic confirmation AML high risk MDS . Elderly cohort ( 70 year age ) : prior chemotherapy treatment AML/high risk MDS currently candidate intensive chemotherapy . Relapsed/refractory cohort ( 18 year age ) : relapse refractory prior treatment . ECOG performance status 0 1 . Total bilirubin &lt; 1.5 x upper limit normal ( ULN ) . AST/SGOT ALT/SGPT &lt; 2.5 x ULN . Serum creatinine &lt; 1.5 x ULN . Patients must read , understand , sign write informed consent form ( ICF ) . Women childbearing potential male patient ' female partner must use acceptable method contraception study , 3 month study drug treatment . Pregnant lactating woman . Patients uncontrolled , intercurrent illness , active uncontrolled infection , fever &gt; 38.5C ( due tumor fever ) day schedule dosing . Patients serious illness medical condition , include laboratory result , , investigator 's opinion , would interfere patient 's participation , interpretation result . Patients treat investigational drug within 30 day prior study initiation . Known hypersensitivity HDAC inhibitor component MG0103 . Known HIV active hepatitis B C. Any condition may affect patient 's ability sign ICF undergo study procedure . Any condition put patient undue risk discomfort result adherence study procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>MDS</keyword>
	<keyword>Phase II</keyword>
	<keyword>Acute Myelogenous Leukemia ( AML )</keyword>
	<keyword>High Risk Myelodysplastic Syndromes ( MDS )</keyword>
</DOC>